Optic Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major optic neuropathy markets reached a value of US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.
The optic neuropathy market has been comprehensively analyzed in IMARC's new report titled "Optic Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Optic neuropathy refers to a medical condition characterized by damage or dysfunction of the optic nerve, which can result in vision loss or impairment. Some of the common symptoms associated with the ailment include gradual or sudden vision loss, blurred or distorted vision, reduced color vision, blank spots, loss of peripheral vision, pain or discomfort around the eye, visual disturbances like flashing lights, etc. The diagnosis of optic neuropathy typically involves a comprehensive evaluation by an eye care specialist, such as an ophthalmologist or neuro-ophthalmologist. The diagnostic process often consists of a thorough medical history review and a detailed examination of visual acuity, pupillary responses, color vision, visual field, and optic nerve appearance using specialized instruments. Various additional procedures may be conducted, including optical coherence tomography (OCT) to assess the structure of the optic nerve, visual evoked potentials (VEP) to measure electrical responses in the visual pathway, numerous imaging studies like MRI or CT scans to identify any underlying causes, etc. Besides this, blood tests may also be performed to check for systemic conditions associated with optic neuropathy.
The increasing cases of direct trauma to the head or eye due to motor vehicle accidents, falls, sports-related injuries, etc., which can result in optic nerve damage, are primarily driving the optic neuropathy market. Furthermore, the rising prevalence of several associated risk factors, such as advancing age, genetic mutations, underlying systemic conditions like diabetes, structural abnormalities in the optic nerve head, etc., is creating a positive outlook for the market. In addition to this, the widespread adoption of neuroprotective agents, including brimonidine and memantine, which work by preventing cell death and promoting nerve regeneration, is also bolstering the market growth. Moreover, numerous key players are making extensive investments in R&D activities to investigate gene therapies for targeting specific genetic mutations that contribute to optic nerve damage. This, in turn, is further acting as another significant growth-inducing factor. Additionally, the escalating utilization of optic nerve regeneration techniques, including the use of growth factors, tissue engineering, biomaterial scaffolds, etc., to promote axonal regrowth and repair the optic nerve, is expected to drive the optic neuropathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the optic neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for optic neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the optic neuropathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the optic neuropathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the optic neuropathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current optic neuropathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the optic neuropathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the optic neuropathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the optic neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of optic neuropathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of optic neuropathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of optic neuropathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with optic neuropathy across the seven major markets?
What is the size of the optic neuropathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of optic neuropathy?
What will be the growth rate of patients across the seven major markets?
Optic Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for optic neuropathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the optic neuropathy market?
What are the key regulatory events related to the optic neuropathy market?
What is the structure of clinical trial landscape by status related to the optic neuropathy market?
What is the structure of clinical trial landscape by phase related to the optic neuropathy market?
What is the structure of clinical trial landscape by route of administration related to the optic neuropathy market?
The optic neuropathy market has been comprehensively analyzed in IMARC's new report titled "Optic Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Optic neuropathy refers to a medical condition characterized by damage or dysfunction of the optic nerve, which can result in vision loss or impairment. Some of the common symptoms associated with the ailment include gradual or sudden vision loss, blurred or distorted vision, reduced color vision, blank spots, loss of peripheral vision, pain or discomfort around the eye, visual disturbances like flashing lights, etc. The diagnosis of optic neuropathy typically involves a comprehensive evaluation by an eye care specialist, such as an ophthalmologist or neuro-ophthalmologist. The diagnostic process often consists of a thorough medical history review and a detailed examination of visual acuity, pupillary responses, color vision, visual field, and optic nerve appearance using specialized instruments. Various additional procedures may be conducted, including optical coherence tomography (OCT) to assess the structure of the optic nerve, visual evoked potentials (VEP) to measure electrical responses in the visual pathway, numerous imaging studies like MRI or CT scans to identify any underlying causes, etc. Besides this, blood tests may also be performed to check for systemic conditions associated with optic neuropathy.
The increasing cases of direct trauma to the head or eye due to motor vehicle accidents, falls, sports-related injuries, etc., which can result in optic nerve damage, are primarily driving the optic neuropathy market. Furthermore, the rising prevalence of several associated risk factors, such as advancing age, genetic mutations, underlying systemic conditions like diabetes, structural abnormalities in the optic nerve head, etc., is creating a positive outlook for the market. In addition to this, the widespread adoption of neuroprotective agents, including brimonidine and memantine, which work by preventing cell death and promoting nerve regeneration, is also bolstering the market growth. Moreover, numerous key players are making extensive investments in R&D activities to investigate gene therapies for targeting specific genetic mutations that contribute to optic nerve damage. This, in turn, is further acting as another significant growth-inducing factor. Additionally, the escalating utilization of optic nerve regeneration techniques, including the use of growth factors, tissue engineering, biomaterial scaffolds, etc., to promote axonal regrowth and repair the optic nerve, is expected to drive the optic neuropathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the optic neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for optic neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the optic neuropathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the optic neuropathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the optic neuropathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current optic neuropathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the optic neuropathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the optic neuropathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the optic neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of optic neuropathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of optic neuropathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of optic neuropathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with optic neuropathy across the seven major markets?
What is the size of the optic neuropathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of optic neuropathy?
What will be the growth rate of patients across the seven major markets?
Optic Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for optic neuropathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the optic neuropathy market?
What are the key regulatory events related to the optic neuropathy market?
What is the structure of clinical trial landscape by status related to the optic neuropathy market?
What is the structure of clinical trial landscape by phase related to the optic neuropathy market?
What is the structure of clinical trial landscape by route of administration related to the optic neuropathy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OPTIC NEUROPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OPTIC NEUROPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OPTIC NEUROPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 OPTIC NEUROPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OPTIC NEUROPATHY - UNMET NEEDS
10 OPTIC NEUROPATHY - KEY ENDPOINTS OF TREATMENT
11 OPTIC NEUROPATHY - MARKETED PRODUCTS
11.1 List of Optic Neuropathy Marketed Drugs Across the Top 7 Markets
11.1.1 Raxone (Idebenone) - Chiesi Farmaceutici/Santhera Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OPTIC NEUROPATHY - PIPELINE DRUGS
12.1 List of Optic Neuropathy Pipeline Drugs Across the Top 7 Markets
12.1.1 GS010 - GenSight Biologics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elamipretide - Stealth BioTherapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OPTIC NEUROPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OPTIC NEUROPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OPTIC NEUROPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Optic Neuropathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Optic Neuropathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Optic Neuropathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Optic Neuropathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Optic Neuropathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Optic Neuropathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Optic Neuropathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Optic Neuropathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Optic Neuropathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Optic Neuropathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Optic Neuropathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Optic Neuropathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Optic Neuropathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Optic Neuropathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Optic Neuropathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Optic Neuropathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Optic Neuropathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Optic Neuropathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Optic Neuropathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Optic Neuropathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Optic Neuropathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Optic Neuropathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Optic Neuropathy - Access and Reimbursement Overview
16 OPTIC NEUROPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OPTIC NEUROPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OPTIC NEUROPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OPTIC NEUROPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OPTIC NEUROPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OPTIC NEUROPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 OPTIC NEUROPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OPTIC NEUROPATHY - UNMET NEEDS
10 OPTIC NEUROPATHY - KEY ENDPOINTS OF TREATMENT
11 OPTIC NEUROPATHY - MARKETED PRODUCTS
11.1 List of Optic Neuropathy Marketed Drugs Across the Top 7 Markets
11.1.1 Raxone (Idebenone) - Chiesi Farmaceutici/Santhera Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OPTIC NEUROPATHY - PIPELINE DRUGS
12.1 List of Optic Neuropathy Pipeline Drugs Across the Top 7 Markets
12.1.1 GS010 - GenSight Biologics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elamipretide - Stealth BioTherapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OPTIC NEUROPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OPTIC NEUROPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OPTIC NEUROPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Optic Neuropathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Optic Neuropathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Optic Neuropathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Optic Neuropathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Optic Neuropathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Optic Neuropathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Optic Neuropathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Optic Neuropathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Optic Neuropathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Optic Neuropathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Optic Neuropathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Optic Neuropathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Optic Neuropathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Optic Neuropathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Optic Neuropathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Optic Neuropathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Optic Neuropathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Optic Neuropathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Optic Neuropathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Optic Neuropathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Optic Neuropathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Optic Neuropathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Optic Neuropathy - Access and Reimbursement Overview
16 OPTIC NEUROPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OPTIC NEUROPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OPTIC NEUROPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
